Total Payments
$97,429
2024 Payments
$236.03
Companies
18
Transactions
290
Payment Breakdown by Category
Other$55,708 (57.2%)
Consulting$19,610 (20.1%)
Travel$7,916 (8.1%)
Food & Beverage$7,236 (7.4%)
Research$6,823 (7.0%)
Education$136.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,208 | 22 | 55.6% |
| Consulting Fee | $19,610 | 7 | 20.1% |
| Travel and Lodging | $7,916 | 37 | 8.1% |
| Food and Beverage | $7,236 | 173 | 7.4% |
| Unspecified | $6,823 | 47 | 7.0% |
| Honoraria | $1,500 | 1 | 1.5% |
| Education | $136.92 | 3 | 0.1% |
Payments by Type
General
$90,606
243 transactions
Research
$6,823
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $56,594 | 75 | $0 (2022) |
| Janssen Products, LP | $23,897 | 36 | $0 (2019) |
| Gilead Sciences, Inc. | $4,318 | 22 | $0 (2020) |
| Synergy Pharmaceuticals Inc | $2,638 | 69 | $0 (2018) |
| GlaxoSmithKline, LLC. | $2,601 | 23 | $0 (2023) |
| Theratechnologies Inc. | $2,023 | 5 | $0 (2018) |
| Merck Sharp & Dohme LLC | $1,829 | 14 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $1,518 | 1 | $0 (2022) |
| AbbVie Inc. | $1,158 | 9 | $0 (2023) |
| Allergan Inc. | $293.28 | 14 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $236.03 | 11 | Madrigal Pharmaceuticals ($236.03) |
| 2023 | $4,662 | 37 | Merck Sharp & Dohme LLC ($1,815) |
| 2022 | $1,559 | 4 | Regeneron Pharmaceuticals, Inc. ($1,518) |
| 2021 | $2,846 | 5 | ViiV Healthcare Company ($2,760) |
| 2020 | $11,503 | 7 | ViiV Healthcare Company ($11,480) |
| 2019 | $53,989 | 103 | ViiV Healthcare Company ($41,174) |
| 2018 | $19,360 | 99 | Janssen Products, LP ($13,515) |
| 2017 | $3,273 | 24 | Gilead Sciences Inc ($2,852) |
All Payment Transactions
290 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $0.98 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: LIVER DISEASE | ||||||
| 11/27/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $3.14 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: LIVER DISEASE | ||||||
| 11/06/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $1.20 | General |
| Category: LIVER DISEASE | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $139.23 | General |
| Category: LIVER DISEASE | ||||||
| 10/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $0.86 | General |
| Category: LIVER DISEASE | ||||||
| 10/09/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: LIVER DISEASE | ||||||
| 12/15/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $149.56 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2023 | AbbVie Inc. | — | — | In-kind items and services | $550.38 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 12/01/2023 | AbbVie Inc. | — | — | In-kind items and services | $82.99 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 12/01/2023 | AbbVie Inc. | — | — | In-kind items and services | $49.79 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 12/01/2023 | AbbVie Inc. | — | — | In-kind items and services | $37.77 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 11/30/2023 | AbbVie Inc. | — | — | In-kind items and services | $192.54 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 11/30/2023 | AbbVie Inc. | — | — | In-kind items and services | $124.48 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 11/30/2023 | AbbVie Inc. | — | — | In-kind items and services | $61.03 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 11/30/2023 | AbbVie Inc. | — | — | In-kind items and services | $43.50 | Research |
| Study: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | ||||||
| 08/22/2023 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $121.65 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/22/2023 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $12.19 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $577.88 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $169.56 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $167.49 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | GlaxoSmithKline, LLC. | $1,542 | 14 |
| AN ADAPTIVE PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING EFFICACY AND SAFETY OF SARILUMAB FOR HOSPITALIZED PATIENTS WITH COVID-19 | Regeneron Pharmaceuticals, Inc. | $1,518 | 1 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,458 | 14 |
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $1,164 | 10 |
| A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 | AbbVie Inc. | $1,142 | 8 |
About Dr. David Stein, M.D
Dr. David Stein, M.D is a Internal Medicine healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326126640.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Stein, M.D has received a total of $97,429 in payments from pharmaceutical and medical device companies, with $236.03 received in 2024. These payments were reported across 290 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($54,208).
Ad
Practice Information
- Specialty Internal Medicine
- Location Bronx, NY
- Active Since 11/02/2006
- Last Updated 03/30/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1326126640
Products in Payments
- DOVATO (Drug) $35,907
- Symtuza (Drug) $13,580
- PREZCOBIX (Drug) $10,318
- Trulance (Drug) $2,638
- TROGARZO (Drug) $2,023
- KEVZARA (Biological) $1,518
- TIVICAY (Drug) $746.07
- DUPIXENT (Biological) $163.34
- VIBERZI (Drug) $152.73
- REZDIFFRA (Drug) $139.23
- LINZESS (Drug) $108.38
- RESMETIROM (Drug) $96.80
- SUCRAID (Drug) $44.78
- ZEPOSIA (Drug) $40.84
- GATTEX (Drug) $34.08
- VRAYLAR (Drug) $32.17
- APRETUDE (Biological) $15.95
- MAVYRET (Drug) $15.16
- VNS Therapy (Device) $14.71
- ZEPATIER (Drug) $14.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bronx
Timothy Kanter, M.d, M.D
Internal Medicine — Payments: $865,160
Internal Medicine $865,160
Dr. Jason Leider, M.d, M.D
Internal Medicine — Payments: $759,257
Internal Medicine $759,257
Bulent Atac, Md, MD
Internal Medicine — Payments: $654,500
Internal Medicine $654,500
Shervin Mortazavi, M.d, M.D
Internal Medicine — Payments: $402,598
Internal Medicine $402,598
Dr. Elizabeth Jenny-Avital
Internal Medicine — Payments: $176,355
Internal Medicine $176,355
Vivek Gumaste, M.d, M.D
Internal Medicine — Payments: $163,229
Internal Medicine $163,229